logo-loader

Northland Capital Partners View on the City - ImmuPharma PLC

no_picture_pai.jpg

ImmuPharma PLC (LON:IMM) – BUY*: £4.1m fund raise

Market Cap: £70m; Current Price: 56p; Target Price: 171p

 

From Friday: £4.1m fund raise further strengthens balance sheet

n  Last Friday ImmuPharma raised a total of £4.1m by way of an issue of 7,884,623 new Ordinary Shares at a price of 52p.

n  Northland Capital Partners acted as sole book runner to the share issue.

n  Major existing and new institutional investors participated in the placing.

n  The funds will: further strengthen the Company's balance sheet as negotiations continue with potential partners for Lupuzor™, its lead programme currently in a pivotal Phase III trial; and support further investment in ImmuPharma's earlier stage portfolio and in particular its P140 peptide platform.

Northland Capital partners view: This successful £4.1m placing further strengthens ImmuPharma’s balance sheet, solidifying the Group’s position in ongoing and future negotiations with potential partners for Lupuzor™, the Company’s flagship late-stage pharmaceutical asset. Lupuzor™, a potential treatment for Lupus, is currently completing a pivotal Phase 3 trial, for which recruitment is now complete. We expect the trial to read out top line results in Q1-18. Should Lupuzor be approved, we estimate it could achieve multi-billion dollar annual sales.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmuPharma PLC named herein, including the promotion by the Company of ImmuPharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Global Energy Metals in London discussing plans to develop cobalt projects...

Global Energy Metals Corporation (CVE:GEMC) (OTCMKTS:GBLEF) CEO Mitchell Smith caught up with Proactive's Andrew Scott while in London to update shareholders on progress within its portfolio of cobalt and battery metal projects. Smith says the firm's well-placed to take advantage of the...

11 hours, 36 minutes ago

2 min read